Birchview Capital LP Sells 140,000 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Birchview Capital LP trimmed its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 70.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 58,000 shares of the medical technology company's stock after selling 140,000 shares during the period. Birchview Capital LP's holdings in Alphatec were worth $532,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in shares of Alphatec by 36.5% during the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock valued at $45,800,000 after buying an additional 1,334,780 shares during the period. Marshall Wace LLP grew its position in Alphatec by 139.2% in the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock worth $16,278,000 after purchasing an additional 1,032,070 shares during the last quarter. Emerald Advisers LLC increased its stake in Alphatec by 112.4% during the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock valued at $13,366,000 after acquiring an additional 770,586 shares during the period. Bank of New York Mellon Corp increased its stake in Alphatec by 119.3% in the fourth quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock valued at $6,079,000 after acquiring an additional 360,258 shares during the period. Finally, Congress Asset Management Co. lifted its holdings in Alphatec by 235.4% during the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock valued at $3,993,000 after purchasing an additional 305,296 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Performance

Shares of NASDAQ:ATEC traded up $0.13 during trading on Thursday, hitting $11.11. 954,733 shares of the company were exchanged, compared to its average volume of 2,046,126. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.79. The stock has a 50 day moving average of $10.42 and a 200 day moving average of $9.78. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The company has a market cap of $1.62 billion, a PE ratio of -8.66 and a beta of 1.20.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. As a group, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Barclays boosted their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Finally, Piper Sandler boosted their price objective on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.67.

Insider Activity at Alphatec

In other Alphatec news, CEO Patrick Miles sold 43,459 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total value of $519,335.05. Following the completion of the sale, the chief executive officer now directly owns 6,065,772 shares of the company's stock, valued at $72,485,975.40. The trade was a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David Sponsel sold 36,256 shares of Alphatec stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the transaction, the executive vice president now owns 735,074 shares in the company, valued at approximately $8,394,545.08. This represents a 4.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 222,113 shares of company stock valued at $2,519,725. Corporate insiders own 22.80% of the company's stock.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.